The search for a better Faslodex continues
Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
Smaller companies set for third-quarter catalysts
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Validation for a drug class, and for Sanofi
If imminent results of Sanofi’s amcenestrant in Ameera-3 are positive Serds could finally see late-stage validation.
A blockbuster breast cancer niche has Roche and Sanofi in the lead
As SAR439859 and RG6171 move into pivotal testing, the Serd approach to treating one form of breast cancer generates renewed interest.
Patience is a virtue for big pharma buyers
For biotechs nearing regulatory approval the key is to sell before launch. For buyers, playing the waiting game is a better strategy.
Go or no go? Ionis, Sanofi, Regeneron and Roche await big regulatory decisions
October looks to be a big month for label expansions, with Dupixent and Hemlibra both poised to move into big new patient populations. Meanwhile Ionis is awaiting a…
After Alnylam’s solo maiden launch, here comes the tricky bit
Alnylam has secured its first approval, but history suggests that launch will be far from easy.
